New hope for rare disease patients in china
NCT ID NCT05054387
Summary
This study tested the safety and effectiveness of Fabrazyme, an enzyme replacement therapy, for Chinese patients with Fabry disease. Twenty-two participants received treatment for 48 weeks while researchers monitored side effects and changes in disease markers. The goal was to understand how well this established treatment works specifically in the Chinese population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :1560001
Shanghai, 200025, China
-
Investigational Site Number :1560002
Beijing, 100730, China
-
Investigational Site Number :1560003
Beijing, 100034, China
-
Investigational Site Number :1560004
Shanghai, 201102, China
-
Investigational Site Number :1560005
Wuhan, 016040, China
-
Investigational Site Number :1560006
Taiyuan, 030001, China
Conditions
Explore the condition pages connected to this study.